Clinical trials: Allergic Rhinoconjunctivitis
House Dust Mite Allergy
Safety and Clinical Tolerability of hdmASIT+TM Peptides Administered in HDM-induced Allergic Patients
hdmASIT+TM product is based on highly purified allergen fragments from house dust mites. The purpose of this study is to assess the safety and clinical tolerability of subcutaneous immunotherapy with hdmASIT+TM in patients with…
- Trial name
- NCT03094845
- Testing
- hdmASIT+TM
- Where
- Germany
- Volunteers
- 36 people
- Sponsor
- ASIT Biotech S.A.
Allergic Rhinitis, Allergic Rhinoconjunctivitis
PURETHAL Birch RUSH Study
This study investigates the safety of two up-dosing regimen. The safety of PURETHAL Birch will be evaluated in a rush regimen (maximum dose reached in 3 injections during 3 weeks) compared to the conventional regimen (maximum…
- Trial name
- NCT01918956
- Testing
- PURETHAL Birch, 20.000 AUM/ml
- Where
- 8 sites in Poland
- Volunteers
- 120 people
- Sponsor
- HAL Allergy
Rhinoconjunctivitis With or Without Allergic Asthma
Study to Assess the Safety and Effectiveness of Beltavac® Polymerized With Alternaria Alternata
Non-interventional Study to Assess the Safety and Effectiveness Profile of a SCIT Therapy With Beltavac® Polymerized With Alternaria alternata in allergic patients
- Trial name
- NCT03604718
- Testing
- Beltavac® Polymerized with Alternaria alternata
- Where
- 13 sites in Spain
- Volunteers
- 65 people
- Sponsor
- Probelte Pharma S.L.U.
Rhinitis; Allergic, With Asthma, Conjunctivitis
Efficacy and Long-Term Safety of Ragweed (Ambrosia Artemisiifolia) Sublingual Tablet in Adults With a History of Ragweed-Induced Rhinoconjunctivitis With or Without Asthma (Study P05233)(COMPLETED)
This study will evaluate the efficacy and safety of ragweed sublingual tablet (SCH 39641/MK-3641) compared with placebo in participants with ragweed-induced rhinoconjunctivitis over a one-year period.
- Trial name
- NCT00783198
- Testing
- SCH 39641 6 Amb a 1-U, SCH 39641 12 Amb a 1-U
- Volunteers
- 565 people
- Sponsor
- ALK-Abelló A/S
Rhinitis, Allergic, Rhinoconjunctivitis
Efficacy and Safety Evaluation of the Treatment of Allergy Against Cupressaceae and Grasses.
A Randomized, Double-Blinded, Placebo-Controlled, Prospective, Multicenter Clinical Trial to Evaluate the Efficacy and Safety of Subcutaneous Immunotherapy in Patients With Rhinitis/Rhinoconjunctivitis With or Without Mild to…
- Conditions
- Rhinitis, Allergic, Rhinoconjunctivitis, Asthma, Allergic
- Trial name
- NCT04898283
- Testing
- 10,000 MG01 +10,000 T521, 30,000 MG01 +10,000 T521
- Where
- 27 sites in Spain
- Volunteers
- 180 people
- Sponsor
- Inmunotek S.L.
Allergy
A Study in Children and Adolescents With Birch Pollen-induced Rhinoconjunctivitis
This is a clinical study in children and adolescents (5-17 years) with allergy to pollen from birch (or related trees). It compares the tree SLIT-tablet with placebo in relieving rhinoconjunctivitis symptoms during the birch/tree…
- Trial name
- TreeTop (NCT04878354)
- Testing
- Tree SLIT-tablet
- Where
- 80 sites in Austria, Belgium and 9 more
- Volunteers
- 952 people
- Sponsor
- ALK-Abelló A/S
Allergy to Cats, Allergic Rhinoconjunctivitis
Effect of holoBLG on Cat Allergic Patients
The aim of the study is to investigate the antigen-unspecific effect of a 3 months supplementation with a food for special medical purposes (FSMP) in form of a lozenge containing beta-lactoglobulin (BLG), iron, retinoic acid…
- Trial name
- NCT05455749
- Testing
- holoBLG
- Where
- Germany
- Volunteers
- 42 people
- Sponsor
- Allergy Therapeutics
House Dust Mite Allergy
SUBLIVAC FIX Mite Mixture Dose Tolerability Study
Allergic rhinitis/rhinoconjunctivitis is a symptomatic disorder of the nose induced by an immunoglobulin E (IgE) mediated inflammatory response. Treatment may involve pharmacotherapy and specific immunotherapy (IT).
- Trial name
- DTS (NCT02345278)
- Testing
- SUBLIVAC FIX Mite mixture
- Where
- 10 sites in Germany
- Volunteers
- 81 people
- Sponsor
- HAL Allergy
Rhinitis, Allergic, Seasonal
Efficacy and Safety Study of RAGWITEK™ (MK-3641) in Children With Ragweed-Induced Rhinoconjunctivitis With or Without Asthma (MK-3641-008)
The purpose of this study is to assess the efficacy and safety of short ragweed pollen allergen extract (MK-3641, SCH 039641, RAGWITEK™) sublingual immunotherapy tablets in children aged 5 to 17 years with ragweed-induced…
- Trial name
- NCT02478398
- Testing
- Short ragweed pollen allergen extract, Self-injectable epinephrine, Albuterol/Salbutamol
- Volunteers
- 1,025 people
- Sponsor
- Merck Sharp & Dohme LLC
Allergic Rhinoconjunctivitis
An Open Trial to Assess the Tolerability of AVANZ Phleum Pratense Immunotherapy
The purpose of this study is to assess the tolerability of AVANZ.
- Trial name
- NCT01454531
- Testing
- AVANZ Phleum pratense
- Where
- 20 sites in Spain
- Volunteers
- 199 people
- Sponsor
- ALK-Abelló A/S
Allergy
Efficacy and Safety Study Of Short Ragweed Pollen Sublingual-Oral Immunotherapy
The primary objective of this study is to demonstrate that SLIT administered pre-and co-seasonally is effective in reducing rhinoconjunctivitis symptoms during the entire short ragweed pollen season.
- Trial name
- NCT01353079
- Testing
- Short Ragweed Pollen Allergenic Extract
- Where
- United States
- Volunteers
- 429 people
- Sponsor
- Greer Laboratories
Seasonal Allergic Rhinitis
A Study of Tolerability and Safety of a New Cumulative Dose of Grass MATA MPL
There is increasing evidence that the effectiveness of allergy immunotherapy to control symptoms of rhinoconjunctivitis is related to the cumulative dose of allergen or allergoid administered during a single regimen of…
- Trial name
- G104 (NCT03931993)
- Testing
- Grass MATA MPL
- Where
- 4 sites in United States
- Volunteers
- 30 people
- Sponsor
- Allergy Therapeutics
Grass Pollen Allergy, Hay Fever
Clinical Efficacy and Safety of gpASIT+TM to Treat Seasonal Allergic Rhinoconjunctivitis
The purpose of the study is to evaluate the efficacy and safety of grass pollen-derived peptides administrated orally to treat seasonal allergic rhinoconjunctivitis.
- Trial name
- NCT01308021
- Testing
- gpASIT+TM
- Where
- 19 sites in Belgium, France and 1 more
- Volunteers
- 202 people
- Sponsor
- BioTech Tools S.A.
Grass Pollen Induced Allergic Rhinoconjunctivitis
Evaluation of the Efficacy and Safety of AVANZ® Phleum Pratense in Grass Pollen-induced Allergic Rhinitis During Controlled Exposure in an Environmental Challenge Chamber
The clinical trial will investigate the efficacy of Avanz Phleum pratense in the treatment of rhinitis in an environmental challenge chamber.
- Trial name
- AV-G-03 (NCT02166268)
- Testing
- AVANZ Phleum pratense 15,000 SQ+
- Where
- Germany
- Volunteers
- 140 people
- Sponsor
- ALK-Abelló A/S
Allergic Rhinitis, Allergic Rhinoconjunctivitis
SUBLIVAC FIX Birch Dose Tolerability/Dose Range Finding
The aim of the study is to determine the optimal effective dose of SUBLIVAC FIX Birch based on reduction of upper airways reactivity after 5 months of treatment with different dosages of SUBLIVAC FIX Birch compared to placebo.
- Trial name
- NCT01639768
- Testing
- SUBLIVAC FIX Birch
- Where
- 20 sites in Czechia, Germany and 1 more
- Volunteers
- 270 people
- Sponsor
- HAL Allergy
Allergic Rhinoconjunctivitis Due to Salsola Kali Pollen
An Open Trial to Assess the Tolerability of AVANZ® Salsola Immunotherapy
This trial is an open, national, multi-centre trial. The trial will be initiated in December 2013 and subjects will receive treatment for 6 weeks.
- Trial name
- AV-X-02 (NCT02065856)
- Testing
- AVANZ Salsola
- Where
- Spain
- Volunteers
- 51 people
- Sponsor
- ALK-Abelló A/S
Rhinitis, Allergic, Rhinoconjunctivitis
Study to Evaluate the Efficacy and Safety of "Allergovac Poliplus" in Polysensitized Patients With Allergic Rhinitis/Rhinoconjunctivitis, With or Without Asthma
This is an observational prospective multicenter clinical study, to evaluate the efficacy and safety of the treatment with Allergovac Poliplus subcutaneous immunotherapy (SCIT) with a mixture of 2 allergenic extracts (pollens or…
- Trial name
- ARES (NCT03821077)
- Testing
- Allergen Immunotherapy (AIT)
- Where
- 10 sites in Spain
- Volunteers
- 122 people
- Sponsor
- Roxall Medicina España S.A
Allergy
A Trial of the ALK Grass Tablet in Subjects With Hayfever
This trial is performed to assess the efficacy and safety of the ALK Grass tablet for treatment of grass pollen induced rhinoconjunctivitis (hayfever).
- Trial name
- NCT00227279
- Testing
- ALK Grass tablet
- Where
- Denmark
- Volunteers
- 634 people
- Sponsor
- ALK-Abelló A/S
Seasonal Allergic Rhinitis
Subcutaneous Immunotherapy Treatment for Patients With Hypersensitivity to Grass Pollen
The objective of this trial is to assess the clinical efficacy of the modified extract (depigmented and polymerised with glutaraldehyde)of the subcutaneous injection of Phleum pratense pollen in the treatment of patients affected…
- Trial name
- NCT00916422
- Testing
- Allergen extract (Phleum pratense)
- Where
- 23 sites in Hungary, Spain
- Volunteers
- 153 people
- Sponsor
- Laboratorios Leti, S.L.
Seasonal Allergic Rhinitis, Hay Fever
Efficacy, Safety and PK of Once or Twice Daily Bilastine (10 or 20 mg) Compared With Placebo in the Symptomatic Treatment of SAR
Evaluate the relative efficacy of four dosing regimens of bilastine tablets (given either once or twice per day) versus placebo in patients with Seasonal Allergic Rhinitis (SAR) in the Mountain Cedar season in south Texas and…
- Conditions
- Seasonal Allergic Rhinitis, Hay Fever, Allergic Conjunctivitis, Hypersensitivity
- Trial name
- NCT00574379
- Testing
- Bilastine
- Where
- 13 sites in United States
- Volunteers
- 805 people
- Sponsor
- Faes Farma, S.A.